2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | - | - | - | - | - | 11.184 | 12.082 | 1.787 | 0 | 0 |
Total Income - EUR | - | - | - | - | - | 11.571 | 16.544 | 4.255 | 0 | 0 |
Total Expenses - EUR | - | - | - | - | - | 4.285 | 28.778 | 9.479 | 200 | 1.370 |
Gross Profit/Loss - EUR | - | - | - | - | - | 7.287 | -12.234 | -5.223 | -200 | -1.370 |
Net Profit/Loss - EUR | - | - | - | - | - | 7.200 | -12.328 | -5.283 | -200 | -1.370 |
Employees | - | - | - | - | - | 2 | 2 | 1 | 0 | 0 |
Check the financial reports for the company - Cryox Vision Regenesis S.r.l.
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Check Financial Rating2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 29.839 | 29.930 | 29.838 | 34.818 | 42.503 | - | - | - | - | - |
Current Assets | - | - | - | - | - | 17.365 | 2.257 | 1.471 | 1.466 | 200 |
Inventories | - | - | - | - | - | 1.276 | 1.401 | 1.370 | 1.374 | 0 |
Receivables | - | - | - | - | - | 9.395 | 13 | 20 | 20 | 110 |
Cash | - | - | - | - | - | 6.694 | 843 | 81 | 71 | 90 |
Shareholders Funds | - | - | - | - | - | 7.243 | -5.222 | -10.389 | -10.622 | -11.959 |
Social Capital | - | - | - | - | - | 0 | 41 | 40 | 41 | 40 |
Debts | - | - | - | - | - | 17.984 | 13.518 | 16.026 | 16.265 | 16.324 |
Income in Advance | - | - | - | - | - | 34.643 | 28.779 | 25.673 | 25.752 | 25.674 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "9604 - 9604" | |||||||||
CAEN Financial Year | 9604 |
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Reports that can be accessed based on the subscription:
Get the contact details for any company and get in touch with it.